CRANBURY, N.J. & SHANGHAI–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic Castration Resistant Prostate Cancer (mCRPC). AC0176 is an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.

“Prostate cancer is one of the most common cancers among men in China, and the speed of increase in its incidence and death rates ranks highest in China. We are excited about the IND clearance of AC0176 in China, after its IND clearance and initiation of the first-in-human Phase 1 study in the US early this year,” said Jie Fan, Ph.D., Chief Executive Officer, Accutar Biotechnology, Inc. “We look forward to accelerating the development of AC0176 and furthering our commitment to bringing innovative medicines to patients worldwide.”

The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0176 treatment in Chinese patients with mCRPC. Accutar expects to begin enrollment of this study in the second half of this year.

About AC0176

AC0176 is an investigational orally bioavailable, chimeric degrader of androgen receptor (AR) for the potential treatment of prostate cancers. AR is a hormonal transcription factor, and plays important roles during prostate cancer onset and progression. In preclinical studies, AC0176 has demonstrated potent and selective AR protein degradation with broad coverage of AR mutants, favorable pharmacological properties, as well as promising anti-tumor activities in animal models.

About Accutar Biotechnology, Inc.

Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.

Be transformative. For patients.

To learn more about Accutar, please visit us at www.accutarbio.com.

Responsibilities

Conduct qualitative and quantitative chemical analyses of lab data for our drug discovery
pipelines with the assistance of developed artificial intelligence (AI) empowered
platform. Write technical papers and reports. Prepare standards and specifications for
operational protocols of drug discovery platform. Coordinate operations of company’s
medchem lab. Coordinate the drug discovery projects within with outsourcing researchers
and in house researchers. Collaborate with computation department to improve the
efficiency, scalability and precision of our drug-discovery platform.

Qualifications

Master’s degree in Chemistry or Chemical Engineering required, and 1 year of
experience in a position involving AI drug discovery management or research required.


Send resume to HR, Accutar Biotechnology, Inc., 800 West El Camino Real, Suite 180,
Mountain View, CA 94040

BROOKLYN, N.Y.–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen receptor signaling inhibitors. AC0176 is an orally bioavailable, chimeric degrader molecule targeting the androgen receptor (AR). AC0176 is currently being evaluated in a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with mCRPC.

“mCRPC is a devastating cancer for men marked by high recurrence rate and poor survival. Receiving Fast Track designation from the FDA highlights the high unmet medical need for mCRPC and acknowledges the potential of AC0176 as a novel treatment for this patient population,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “AC0176 was designed to potently degrade both AR wildtype and prevalent AR mutations which confer drug resistance to current AR signaling inhibitors. We look forward to continued interaction with FDA as we quickly advance the development of this potentially promising treatment option for patients in need.”

About Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate cancer (PC) is the second most commonly diagnosed cancer among men worldwide, and the first among men in the United States. mCRPC is a lethal diagnosis, and more effective therapeutic approaches are urgently needed for patients, particularly those who progressed on AR signaling inhibitors. AR-reactivating mechanisms conferring resistance to AR signaling inhibitors include, AR amplification and overexpression, AR point mutations, AR splicing variants, intra-tumoral androgen synthesis, promiscuous AR activation by other factors, etc.

About AC0176

AC0176 is an investigational orally bioavailable, chimeric degrader of AR for the potential treatment of prostate cancers. In preclinical studies, AC0176 demonstrated potent and selective AR protein degradation, favorable pharmacological properties, as well as promising anti-tumor activity in animal models. AC0176 was designed to have broad coverage of AR wildtype and prevalent AR mutations, including but not limited to L702H, T878A, H875Y, W742C. AC0176 is being evaluated in a Phase 1 clinical trial, and information on the study can be found on www.clinicaltrials.gov (NCT05241613).

About Accutar Biotechnology, Inc.

Accutar is a clinical stage biotech company focused on AI-enabled drug discovery, and its application to the discovery and development of clinically differentiated medicines.

Be transformative. For patients.

To learn more about Accutar, please visit us at www.accutarbio.com.

Location: Accutar Biotechnology, Cranbury, New Jersey.

Accutar Biotechnology is a clinical stage biotech company focused on AI-enabled drug discovery, and its application to the discovery and development of clinically differentiated medicines.  We are seeking a talented and self-motivated research associate to join our exciting drug discovery effort. 

Responsibilities

Qualifications:

Position will be hired based on level of experience.

Accutar Biotech offers a competitive compensation in industry, friendly and rewarding working and training environment, and excellent growth potential.

To apply for this position, please send your CV to biocareer@accutarbio.com

Location: Accutar Biotechnology, Cranbury, New Jersey.

Accutar Biotechnology is a clinical stage biotech company focused on AI-enabled drug discovery, and its application to the discovery and development of clinically differentiated medicines.  We are seeking a highly diligent, energetic, and self-motivated scientist with a proven track record of accomplishment in the field of cancer biology to join our exciting drug discovery effort. 

Responsibilities:

The position offers a unique opportunity for a talented scientist to develop his/her career involving a broad scope of drug discovery in a fast-paced research environment.

Qualifications:

Position will be hired based on level of experience.

Accutar Biotech offers a competitive compensation in industry, friendly and rewarding working and training environment, and excellent growth potential.

To apply for this position, please send your CV to biocareer@accutarbio.com

Location: Accutar Biotechnology, Cranbury, New Jersey. 

Accutar Biotechnology is a clinical stage biotech company focused on AI-enabled drug discovery, and its application to the discovery and development of clinically differentiated medicines.  We are seeking a highly diligent, energetic, and self-motivated scientist with a proven track record of accomplishment in the field of immune-oncology or immunology to join our exciting drug discovery effort.  

Responsibilities:

The position offers a unique opportunity for a talented scientist to develop his/her career involving a broad scope of drug discovery in a fast-pace research environment.

Qualifications:

Accutar Biotech offers a competitive compensation in industry, friendly and rewarding working and training environment, and excellent growth potential.

To apply for this position, please send your CV to biocareer@accutarbio.com

纽约布鲁克林 & 中国上海–(BUSINESS WIRE)–(Accutar Biotechnology, Inc.),一家专注于人工智能药物研发的临床阶段生物技术公司,今天宣布国家药品监督管理局(NMPA)已批准该公司在研药物AC0682用于治疗雌激素受体阳性乳腺癌患者的试验用新药申请(IND)。AC0682是一种口服嵌合降解剂分子,可高效选择性地靶向降解雌激素受体蛋白。AC0682也成为全球范围内第一个获得FDA以及NMPA许可,进入临床试验的口服雌激素受体嵌合降解剂。

“乳腺癌是中国女性中最常见的癌症。我们很高兴AC0682 在中国IND获批,这是该药在去年底获得美国IND批准并启动美国1期临床研究之后的又一个里程碑。” 冰洲石生物首席执行官范捷博士说,“我们期待加速AC0682的临床研发,并进一步履行我们为全球癌症患者带来创新药物的承诺。”

中国1期临床研究将评估AC0682治疗中国雌激素受体阳性乳腺癌患者的安全性、耐受性、药代动力学和初步抗肿瘤活性。冰洲石生物预计将于今年下半年在中国启动1期临床试验。

关于 AC0682

AC0682是一种在研口服雌激素受体嵌合降解剂,用于治疗雌激素受体阳性乳腺癌。雌激素受体是一种雌激素调节的转录因子,在乳腺癌的发生和增殖中起关键作用,近 80% 的乳腺癌表达雌激素受体。在临床前研究中,AC0682证明了有效和选择性的雌激素受体蛋白降解,具有良好的药理特性,以及在动物肿瘤模型中具有良好的抗肿瘤活性。

关于冰洲石生物(Accutar Biotechnology, Inc.

Accutar 是一家临床阶段的生物技术公司,专注于人工智能支持的药物设计,尤其是临床差异化药物的研发。

变革治疗。心系患者。

欲了解有关Accutar的更多信息,请访问www.accutarbio.com

BROOKLYN, N.Y. & SHANGHAI–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the company’s investigational new drug application (IND) for AC0682 for the treatment of patients with estrogen receptor (ER)-positive breast cancers. AC0682 is an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity.

“Breast cancer is the most common cancer among women in China. We are excited about the IND clearance of AC0682 in China, after its IND clearance and initiation of a Phase 1 study in the US late last year,” said Jie Fan, Ph.D., Chief Executive Officer, Accutar Biotechnology, Inc. “We look forward to accelerating the development of AC0682 and furthering our commitment to bringing innovative medicines to patients worldwide.”

The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0682 treatment in Chinese patients with ER-positive breast cancer. Accutar expects to begin enrollment of this study in the second half of this year.

About AC0682

AC0682 is an investigational orally bioavailable, chimeric degrader of ERα for the potential treatment of ER-positive breast cancers. ERα is a hormone-regulated transcription factor that plays a critical role in breast cancer initiation and proliferation, and nearly 80% of breast cancers express ERα. In preclinical studies, AC0682 demonstrated potent and selective ERα protein degradation with favorable pharmacological properties, as well as promising anti-tumor activity in ER-positive animal tumor models.

About Accutar Biotechnology, Inc.

Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.

Be transformative. For patients.

To learn more about Accutar, please visit us at www.accutarbio.com.

– Chimeric Degrader With a Differentiated Mechanism of Action vs. Androgen Receptor Inhibitors –

– Broad AR Mutant Coverage Designed to Overcome Resistance to Current AR-Targeted Therapies –

BROOKLYN, N.Y.–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0176, an orally bioavailable, chimeric degrader molecule designed to target the androgen receptor (AR) with high potency and selectivity.

“The initiation of this study marks the second program from our AI-enabled drug discovery platform and our chimeric degrader portfolio to enter the clinic,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “AC0176 was designed to potently degrade both AR wildtype and prevalent AR mutants which confer drug resistance to current AR-targeted therapies, including but not limited to L702H, T878A, H875Y, W742C. We are excited about the differentiated therapeutic profile of AC0176 and its broad potential to treat prostate cancer patients.”

The purpose of the Phase 1 multi-center, open-label study is to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0176 treatment in patients with mCRPC. Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05241613).

About AC0176

AC0176 is an investigational orally bioavailable, chimeric degrader of AR for the potential treatment of prostate cancers. In preclinical studies, AC0176 demonstrated potent and selective AR protein degradation with broad coverage of AR mutants, favorable pharmacological properties, as well as promising anti-tumor activity in animal models.

About Accutar Biotechnology, Inc.

Accutar is a clinical stage biotech company focused on AI-enabled drug discovery, and its application to the discovery and development of clinically differentiated medicines.

Be transformative. For patients.

To learn more about Accutar, please visit us at www.accutarbio.com.

Accutar Biotech Inc., a biotechnology company specializing in artificial intelligence (AI)-empowered drug discovery, today announced that Dr. Alexander Varshavsky, a world leader in the ubiquitination system, has joined the Scientific Advisory Board (SAB) of the company to advise on novel E3 ligase discovery programs.

“It is our great honor and privilege to have Dr. Varshavsky join our SAB”, said Jie Fan, PhD, founder and CEO of Accutar. “Dr. Varshavsky’s pioneering work in ubiquitination and the N-degron pathway of protein degradation has opened up a whole new field for basic science and for the pharmaceutical industry with tremendous potential. Dr. Varshavsky’s unique insights and vision has further improved our confidence to move forward on our first-in-class E3 ligase inhibitor programs with the hope of bringing brighter futures to patients.”